Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

Zacks Equity Research

26 April 2024 at 9:23 am·4-min read

We expect Fusion Pharmaceuticals FUSN to beat expectations when it reports first-quarter 2024 results. Without a marketed product, investors will focus on the upcoming earnings call for updates regarding Fusion’s pipeline candidates.

In March 2024, Fusion signed a definitive agreement with AstraZeneca AZN, where the latter will acquire all outstanding shares of FUSN for $21 per share in cash, aggregating to $2 billion.The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions and clearance from regulatory authorities.

Let's see how things might have shaped up in the to-be-reported quarter.

Factors to Consider

Fusion makes next-generation radiopharmaceuticals as precision medicines. It has a diversified pipeline of targeted alpha therapy (TAT) programs.

The company’s lead product candidate, FPI-2265, is a small molecule-based TAT targeting prostate-specific membrane antigen to treat cancer.

In January 2024, Fusion announced that it has aligned with the FDA regarding the phase II/III study protocols for FPI-2265 in previously treated metastatic castration-resistant prostate cancer (mCRPC) patients. The phase II dose-optimization portion of the study is expected to begin in the second quarter of 2024.

Subject to positive results from the mid-stage portion of the study and upon reaching alignment with the FDA regarding the recommended late-stage dosing strength, the company anticipates initiating the phase III global registrational study in 2025. Further updates regarding the planned mid to late-stage mCRPC study are expected in the first-quarter earnings release.

The company has two other candidates, FPI-1434 and FPI-2059, which are currently being developed in separate early-stage studies for patients with solid tumors expressing IGF-1R and NTSR1, respectively.

Fusion reported positive initial findings from the phase I study of FPI-1434 in January 2024. The company is likely to share further updates from the study in mid-2024.

FUSN has a collaboration with AstraZenecato jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors and immuno-oncology agents. Its revenues comprise periodic collaboration revenues from its partnership with AZN.

Currently, Fusion and AstraZeneca are jointly developing FPI-2068, a bispecific IgG-based TAT, in an early-stage study for solid tumor indications expressing EGFR-cMET, which include head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma.

Fusion expects to initiate a combination study of FPI-2265 plus Merck MRK/AstraZeneca’s Lynparza (Olaparib) in earlier lines of mCRPC treatment in the first half of 2024.

The company has collaborated with Merck to evaluate FPI-1434 in combination with the latter’s blockbuster PD-L1 inhibitor, Keytruda, in patients with solid tumors expressing IGF-1R. The company is expected to provide an update regarding the same in the upcoming earnings release.

Earnings Surprise History

The company’s earnings surpassed estimates in two of the trailing four quarters and missed on the other two occasions, delivering an average negative surprise of 7.46%.

Year to date, shares of FUSN have skyrocketed 122.7% against the industry’s 12% decline.

Image Source: Zacks Investment Research

Earnings Whisper

Our proven model predicts an earnings beat for Fusion this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: Fusion has an Earnings ESP of +0.34%. The Zacks Consensus Estimate for earnings is currently pegged at 37 cents.

Zacks Rank: FUSN currently carries a Zacks Rank #3.

Fusion Pharmaceuticals Inc. Price and EPS Surprise

Fusion Pharmaceuticals Inc. price-eps-surprise | Fusion Pharmaceuticals Inc. Quote

Other Stock to Consider

Here is another stock worth considering from the healthcare space, as our model shows that it has the right combination of elements to beat on earnings this reporting cycle.

Sarepta Therapeutics SRPT has an Earnings ESP of +108.99% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of Sarepta Therapeutics have gained 32.1% in the year-to-date period. SRPT’s earnings beat estimates in each of the last four quarters, delivering an average surprise of 464.56%.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report

Fusion Pharmaceuticals Inc. (FUSN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The Smart Investor
4 Singapore Blue-Chip Stocks You Can Buy and Hold Forever
We highlight four solid blue-chip names that you can buy and safely own for the rest of your life. The post 4 Singapore Blue-Chip Stocks You Can Buy and Hold Forever appeared first on The Smart Investor.
Simply Wall St.
Unveiling 3 Top Dividend Stocks In Singapore With Yields Up To 8.5%
As the Singapore market continues to navigate through global economic challenges, including inflation and interest rate adjustments, investors are increasingly looking for stable returns. Dividend stocks, known for their potential to provide regular income, become particularly appealing in such uncertain times.
Barrons.com
Palantir Earnings Crush Estimates. Why Some Investors Are Selling on the News.
Palantir followed up its “bombastic” December quarter with even better results for the March quarter as the data analytics software company continued to gain traction with its artificial-intelligence tools, in particular with U.S. commercial customers. Palantir shares, which rallied 8.1% in Monday’s regular session, were down more than 14% to $21.56 in midday trading Tuesday. For the March quarter, Palantir posted revenue of $634 million, up 21% from a year ago, and ahead of both the company’s guidance range of $612 million to $616 million and Wall Street’s consensus of $615 million as tracked by FactSet.
GOBankingRates
Warren Buffett Invested $74 Billion in This Stock — Should You Invest Too?
Known as the Oracle of Omaha, Warren Buffett is one of the most successful investors of all time. He started his first investment partnership in 1956 with a few friends and family. An investment in...
Simply Wall St.
Is It Time To Consider Buying Hutchison Port Holdings Trust (SGX:NS8U)?
Hutchison Port Holdings Trust ( SGX:NS8U ), is not the largest company out there, but it received a lot of attention...
Simply Wall St.
Is Thai Beverage Public Company Limited's (SGX:Y92) Recent Stock Performance Influenced By Its Financials In Any Way?
Thai Beverage's (SGX:Y92) stock is up by 3.2% over the past week. We wonder if and what role the company's financials...
The Hill
Starbucks needs to refocus on coffee, former CEO says
Former Starbucks CEO Howard Schultz urged his successors to get back to basics as the company sees falling sales. Schultz said in a LinkedIn post that leaders should focus on spending time in stores and on providing good coffee rather than other management strategies. “At any company that misses badly, there must be contrition and…
Fortune
$3 trillion could be injected into the U.S. economy without any federal spending by tweaking this corner of the mortgage market, ‘Oracle of Wall Street’ says
"Rarely have I seen such a true win-win scenario for the government, Wall Street and the U.S. consumer."
The Edge Singapore
Singapore reviewing proposal by SVCA to revive local stock market: FT
'There has been a shift in thinking by the government that this is not just an SGX problem'
Yahoo Finance
Stock market today: Stocks climb as S&P 500 notches best 3-day run of 2024
Stocks rallied at the end of last week, getting a boost from a "Goldilocks" jobs report.
Yahoo Finance
Stock market today: Stocks edge higher, Disney sinks after earnings
Results from Disney took center stage as the media giant posted the first profit for a key part of its streaming business.
Yahoo Finance
The biggest risk to investing in 'Magnificent 7' stocks like Nvidia and Amazon, according to top CEOs
It's good practice for investors to think beyond the "Magnificent Seven" stocks, the CEOs of Apollo and Avenue Capital Group said.
Reuters
Gold gains on soft dollar, rate cut hopes
Gold prices climbed more than 1% on Monday, as the U.S. dollar weakened after softer-than-expected U.S. jobs data fueled expectations of potential interest rate cuts by the Federal Reserve later this year. Spot gold rose 1% to $2,324.94 per ounce by 2:00 p.m. ET (1800 GMT). "The downside that we've seen over the last few weeks might actually be running out of steam, opening (the) door for gold prices to resume their upward trajectory," said Daniel Ghali, commodity strategist at TD Securities.
Reuters
Toyota to get an earnings lift from hybrids as EV hype cools
Toyota Motor is expected to get a big lift from demand for hybrids when it reports annual earnings on Wednesday, illustrating how the world's top-selling automaker is poised to benefit as hype around battery electric vehicles cools. But the forecast record results, to be helped in part by a boost from the weak yen currency, belie the considerable challenges it faces in critical markets. In China it is pressured by a ferocious price war and in the U.S., the fallout from consumers grappling with higher borrowing costs.
Simply Wall St.
3 Growth Companies With High Insider Ownership And At Least 12% Revenue Growth
Amid a buoyant U.S. stock market, bolstered by robust first-quarter earnings and the anticipation of interest rate cuts, investors are keenly observing various factors that could influence their investment decisions. In this context, growth companies with high insider ownership and significant revenue growth present an interesting opportunity for those looking to align with the confidence insiders are showing in their own companies.
Reuters
GLOBAL MARKETS-Asia shares rally on Fed cut bets; yen pares gains
Asian stocks rose on Monday on renewed bets that the Federal Reserve would likely ease rates this year, while the yen weakened after a strong surge last week from Tokyo's suspected currency intervention. Trading was thinned in Asia with Japan out for a holiday, though markets in mainland China got off to an upbeat start after returning from an extended break. MSCI's broadest index of Asia-Pacific shares outside Japan edged more than 0.5% higher, while China's blue-chip index gained 1.4%.
Reuters
EMERGING MARKETS-Asian stocks extend gains on Fed rate cut optimism, FX down on firm dollar
(.) * South Korean shares jump as much as 2.2% * Taiwan's April CPI due later in the day * Malaysia rate decision due on Thursday By Ayushman Ojha May 7 (Reuters) - Most Asian stock markets extended gains on Tuesday on the back of renewed bets for U.S. rate cuts after last week's cooler-than-expected jobs data, while the region's currencies were subdued as the dollar ticked higher. Regional markets are still cautious about the future path of U.S. interest rates as they have not seen a strengthening in Asian currencies even with U.S. yields falling, said Lloyd Chan, senior currency analyst at MUFG Bank. Taiwan is scheduled to report its April inflation numbers later on Tuesday.
GOBankingRates
I’m a Financial Advisor: These Are the 6 Biggest Money Mistakes People Make in Their 50s
Financial planning is important at all stages of your adult life, but it's doubly so once you reach your 50s. It's around this point where many people start thinking more seriously about retirement....
Benzinga
AMD Positions for AI Leadership with Expanded Portfolio, Quadrupled R&D Investment Ahead of Major Computex Announcements
Advanced Micro Devices, Inc (NASDAQ:AMD) is strategically preparing to address the growing demand for AI computing by leveraging its extensive product range. CTO Mark Papermaster emphasized AMD’s robust portfolio of compute engines, strong relationships with customers across diverse markets, and open software capabilities. He reflected on AMD’s 55-year history, highlighting its shift to a modular IP portfolio unified by a comprehensive AI software stack, which will enable the company to adapt mo
Deadline
Disney Stock Dips As Theme Park Comments Rattle Market; CFO Cites “Global Moderation From Peak Post-Covid Travel”
Fireworks at Disney’s first-quarter earnings amid a bitter proxy fight quieted down in the second and the company’s commentary on a call today, especially around the parks business, generated some investor angst and knocked the stock lower. Disney shares are down nearly 10% late morning at about $105. Parks, as has been the pattern, was …

Straits Times Index

S&P 500

Dow

Nasdaq

Bitcoin USD

CMC Crypto 200

FTSE 100

Gold

Crude Oil

10-Yr Bond

Nikkei

Hang Seng

FTSE Bursa Malaysia

Jakarta Composite Index

PSE Index

Factors to Consider

Earnings Surprise History

Earnings Whisper

Fusion Pharmaceuticals Inc. Price and EPS Surprise

Other Stock to Consider

Latest stories